- Home
- IMUX vs CODA Comparison
IMUX vs CODA Comparison
Compare IMUX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- CODA
- Stock Information
- Founded
- IMUX 2016
- CODA 1994
- Country
- IMUX United States
- CODA United States
- Employees
- IMUX N/A
- CODA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- CODA Industrial Machinery/Components
- Sector
- IMUX Health Care
- CODA Industrials
- Exchange
- IMUX Nasdaq
- CODA Nasdaq
- Market Cap
- IMUX 67.8M
- CODA 88.7M
- IPO Year
- IMUX N/A
- CODA N/A
- Fundamental
- Price
- IMUX $0.83
- CODA $8.10
- Analyst Decision
- IMUX Strong Buy
- CODA Strong Buy
- Analyst Count
- IMUX 6
- CODA 1
- Target Price
- IMUX $11.60
- CODA $11.00
- AVG Volume (30 Days)
- IMUX 1.7M
- CODA 59.6K
- Earning Date
- IMUX 08-07-2025
- CODA 06-16-2025
- Dividend Yield
- IMUX N/A
- CODA N/A
- EPS Growth
- IMUX N/A
- CODA 21.86
- EPS
- IMUX N/A
- CODA 0.30
- Revenue
- IMUX N/A
- CODA $22,758,966.00
- Revenue This Year
- IMUX N/A
- CODA $11.64
- Revenue Next Year
- IMUX N/A
- CODA $14.53
- P/E Ratio
- IMUX N/A
- CODA $26.83
- Revenue Growth
- IMUX N/A
- CODA 24.78
- 52 Week Low
- IMUX $0.56
- CODA $5.76
- 52 Week High
- IMUX $2.11
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- IMUX 55.91
- CODA 57.37
- Support Level
- IMUX $0.68
- CODA $7.81
- Resistance Level
- IMUX $0.83
- CODA $8.50
- Average True Range (ATR)
- IMUX 0.05
- CODA 0.41
- MACD
- IMUX 0.02
- CODA -0.01
- Stochastic Oscillator
- IMUX 88.50
- CODA 63.45
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.